Financing ·
Jaguar Health executed multiple equity transactions in mid-September 2026 to raise capital and consolidate ownership…
JAGXJaguar Health, Inc.
Jaguar Health executed multiple equity transactions in mid-September 2026 to raise capital and consolidate ownership of its Italian subsidiary, Napo Therapeutics. On September 11, the company exchanged a $175,016.36 convertible promissory note held by Lincoln Alternative Strategies for 557,377 shares of common stock. Simultaneously, it converted Series Q Preferred Stock held by Streeterville Capital into 304,473 total common shares across three agreements dated July 7, September 11, and September 14. Additionally, on September 12, Jaguar Health entered a securities purchase agreement to acquire the remaining minority stake in Napo Therapeutics from a related party by issuing 535,000 common shares and a pre-funded warrant for 2,077,255 shares; this transaction closed on September 15. These actions represent significant unregistered equity issuances and strategic consolidation of its pharmaceutical subsidiary.